Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAD52 | P43351 | 5/20 | 0.60 |
| ▸ | TOP2A | P11388 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 9/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596040 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL4601686 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL4603873 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL14595998 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL14596000 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL30125367 | 0.80 | POLB (0.70) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL8906802 | 0.80 | POLB (0.70) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL14596003 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL14596026 | 0.79 | ALDH1A1 (0.57) | ALDH1A1MAPK1RAD52TOP2APOLB | |
| SCHEMBL13159119 | 0.79 | ALDH1A1 (0.57) | ALDH1A1MAPK1RAD52TOP2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790474-B1 | p53 modulators | SCHERING CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790474-B1 | p53 modulators | SCHERING CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | ALDH1A1 1994/4885MAPK1 2089/4885RAD52 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.